Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Research ArticleBasic Science Investigation

Influence of Fc Modifications and IgG Subclass on Biodistribution of Humanized Antibodies Targeting L1CAM

Sai Kiran Sharma, Maya Suzuki, Hong Xu, Joshua A. Korsen, Zachary Samuels, Hongfen Guo, Brandon Nemieboka, Alessandra Piersigilli, Kimberly J. Edwards, Nai-Kong V. Cheung and Jason S. Lewis
Journal of Nuclear Medicine April 2022, 63 (4) 629-636; DOI: https://doi.org/10.2967/jnumed.121.262383
Sai Kiran Sharma
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maya Suzuki
2Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York;
3Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hong Xu
2Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York;
4Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joshua A. Korsen
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York;
5Department of Pharmacology, Weill Cornell Medical College, New York, New York;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zachary Samuels
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hongfen Guo
2Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York;
4Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brandon Nemieboka
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York;
6Gerstner Sloan Kettering Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, New York;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alessandra Piersigilli
7Tri-Institutional Laboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, and Rockefeller University, New York, New York;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kimberly J. Edwards
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nai-Kong V. Cheung
2Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York;
5Department of Pharmacology, Weill Cornell Medical College, New York, New York;
6Gerstner Sloan Kettering Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, New York;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason S. Lewis
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York;
4Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York;
6Gerstner Sloan Kettering Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, New York;
8Department of Radiology, Weill Cornell Medical College, New York, New York; and
9Radiochemistry and Molecular Imaging Probes Core, Memorial Sloan Kettering Cancer Center, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Visual Abstract

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Abstract

Immuno-PET is a powerful tool to noninvasively characterize the in vivo biodistribution of engineered antibodies. Methods: L1 cell adhesion molecule–targeting humanized (HuE71) IgG1 and IgG4 antibodies bearing identical variable heavy- and light-chain sequences but different fragment crystallizable (Fc) portions were radiolabeled with 89Zr, and the in vivo biodistribution was studied in SKOV3 ovarian cancer xenografted nude mice. Results: In addition to showing uptake in L1 cell adhesion molecule–expressing SKOV3 tumors, as does its parental counterpart HuE71 IgG1, the afucosylated variant having enhanced Fc-receptor affinity showed high nonspecific uptake in lymph nodes. On the other hand, aglycosylated HuE71 IgG1 with abrogated Fc-receptor binding did not show lymphoid uptake. The use of the IgG4 subclass showed high nonspecific uptake in the kidneys, which was prevented by mutating serine at position 228 to proline in the hinge region of the IgG4 antibody to mitigate in vivo fragment antigen-binding arm exchange. Conclusion: Our findings highlight the influence of Fc modifications and the choice of IgG subclass on the in vivo biodistribution of antibodies and the potential outcomes thereof.

  • immuno-PET
  • aglycosylated antibody
  • afucosylated antibody
  • Fab arm exchange

Footnotes

  • Published online August 05, 2021.

  • © 2022 by the Society of Nuclear Medicine and Molecular Imaging.
View Full Text

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Login to the site using your SNMMI member credentials

Individuals

Non-Member Login

Login as an individual user

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 63 (4)
Journal of Nuclear Medicine
Vol. 63, Issue 4
April 1, 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Influence of Fc Modifications and IgG Subclass on Biodistribution of Humanized Antibodies Targeting L1CAM
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Influence of Fc Modifications and IgG Subclass on Biodistribution of Humanized Antibodies Targeting L1CAM
Sai Kiran Sharma, Maya Suzuki, Hong Xu, Joshua A. Korsen, Zachary Samuels, Hongfen Guo, Brandon Nemieboka, Alessandra Piersigilli, Kimberly J. Edwards, Nai-Kong V. Cheung, Jason S. Lewis
Journal of Nuclear Medicine Apr 2022, 63 (4) 629-636; DOI: 10.2967/jnumed.121.262383

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Influence of Fc Modifications and IgG Subclass on Biodistribution of Humanized Antibodies Targeting L1CAM
Sai Kiran Sharma, Maya Suzuki, Hong Xu, Joshua A. Korsen, Zachary Samuels, Hongfen Guo, Brandon Nemieboka, Alessandra Piersigilli, Kimberly J. Edwards, Nai-Kong V. Cheung, Jason S. Lewis
Journal of Nuclear Medicine Apr 2022, 63 (4) 629-636; DOI: 10.2967/jnumed.121.262383
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Enhancing 223Ra Treatment Efficacy by Anti-β1 Integrin Targeting
  • Radioembolization Dosimetry with Total-Body 90Y PET
  • Glypican-3–Targeted 227Th α-Therapy Reduces Tumor Burden in an Orthotopic Xenograft Murine Model of Hepatocellular Carcinoma
Show more Basic Science Investigation

Similar Articles

Keywords

  • immuno-PET
  • aglycosylated antibody
  • afucosylated antibody
  • Fab arm exchange
SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire